Topics

Amgen and Novartis discontinue Alzheimer’s drug development programme

06:09 EDT 12 Jul 2019 | Pharmaceutical Technology

Amgen and Novartis have announced the discontinuation of their clinical development programme for CNP520 (umibecestat), a BACE1 inhibitor for Alzheimer’s...
Read More...

The post Amgen and Novartis discontinue Alzheimer’s drug development programme appeared first on Pharmaceutical Technology.

Original Article: Amgen and Novartis discontinue Alzheimer’s drug development programme

NEXT ARTICLE

More From BioPortfolio on "Amgen and Novartis discontinue Alzheimer’s drug development programme"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...